比较急性冠状动脉综合征行经皮冠状动脉介入治疗患者中普拉格雷和替格瑞洛的有效性和安全性：倾向评分匹配分析。
Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis.
机构信息
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Pharmacology, All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh, India.
出版信息
Indian Heart J. 2024 Mar-Apr;76(2):133-135. doi: 10.1016/j.ihj.2024.03.001. Epub 2024 Mar 13.
Evidence on comparative effectiveness and safety of prasugrel and ticagrelor post-percutaneous transluminal coronary angioplasty is scarce in Indian population. In a 1:1 propensity score-matched cohort with 71 individuals in each group, the incidence of a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization was not significantly different in prasugrel and ticagrelor group (7.04% vs 9.86%; absolute difference, 2.8%; HR, 0.65; 95% CI, 0.21-2.1; p = 0.49). There was no significant difference in bleeding (5.63% vs 9.86%; absolute difference, -4.20%; 95% CI, -13.0%-4.5%) and dyspnea (7.04% vs 12.7%; absolute difference, -5.60%; 95% CI, -15.4%-4.1%).
普拉格雷和替格瑞洛经皮腔内冠状动脉成形术后在印度人群中的有效性和安全性比较证据稀缺。在一项 1:1 的倾向评分匹配队列中，每组各有 71 名患者，普拉格雷和替格瑞洛组的心血管死亡、非致死性心肌梗死、非致死性卒中和冠状动脉血运重建的复合发生率无显著差异（7.04% vs 9.86%；绝对差异，2.8%；HR，0.65；95%CI，0.21-2.1；p=0.49）。出血（5.63% vs 9.86%；绝对差异，-4.20%；95%CI，-13.0%-4.5%）和呼吸困难（7.04% vs 12.7%；绝对差异，-5.60%；95%CI，-15.4%-4.1%）也无显著差异。
Zotero 插件